Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: XENICAL

« Back to Dashboard
Xenical is a drug marketed by Hoffmann La Roche and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug.

The generic ingredient in XENICAL is orlistat. There are nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the orlistat profile page.

Summary for Tradename: XENICAL

Suppliers / Packagers: see list7

Pharmacology for Tradename: XENICAL

Clinical Trials for: XENICAL

Study of Fat Malabsorption by Lipiblock Versus Xenical
Status: Completed Condition: Obesity

Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Trials
Status: Completed Condition: Obesity

Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus
Status: Completed Condition: Fatty Liver; Hepatitis C

Orlistat Induced Modulation on the Fatty Acid Composition in Obese Females
Status: Completed Condition: Overweight

Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases
Status: Completed Condition: Diabetes Mellitus; Hypertension; Metabolic Disease; Obesity; Sleep Apnea Syndrome

Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder
Status: Completed Condition: Overweight; Eating Disorders

Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union.
Status: Not yet recruiting Condition: Weight Loss

The Effect of Xenical on Weight and Risk Factors
Status: Completed Condition: Obesity; Heart Diseases

A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss
Status: Completed Condition: Diabetes Mellitus; Obesity

Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients
Status: Completed Condition: Obesity

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche
CAPSULE;ORAL020766-001Apr 23, 1999RXYes6,004,996*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn